Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

ClinicalTrials.gov ID: NCT02347176

Public ClinicalTrials.gov record NCT02347176. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis

Study identification

NCT ID: NCT02347176
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 204 participants

Conditions and interventions

Conditions

Atopic Dermatitis

Interventions

Other · Biological

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 22, 2015
Primary completion: Nov 26, 2015
Completion: Feb 4, 2016
Last update posted: May 22, 2018

2015 – 2016

United States locations

U.S. sites: 24
U.S. states: 12
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research Site	Phoenix	Arizona	85018	—
Research Site	Rogers	Arkansas	72758	—
Research Site	Fremont	California	94538	—
Research Site	Fullerton	California	92835	—
Research Site	Los Angeles	California	90045	—
Research Site	Oceanside	California	92056	—
Research Site	Rancho Santa Margarita	California	92688	—
Research Site	Santa Monica	California	90404	—
Research Site	Clearwater	Florida	33759	—
Research Site	Miami	Florida	33144	—
Research Site	Worcester	Massachusetts	01605	—
Research Site	Warren	Michigan	48088	—
Research Site	Berlin	New Jersey	08009	—
Research Site	Verona	New Jersey	07044	—
Research Site	New York	New York	10029	—
Research Site	Rochester	New York	14625	—
Research Site	Portland	Oregon	97241	—
Research Site	Charleston	South Carolina	29414	—
Research Site	Houston	Texas	77004	—
Research Site	Houston	Texas	77056	—
Research Site	Pflugerville	Texas	78660	—
Research Site	San Antonio	Texas	78218	—
Research Site	San Antonio	Texas	78229	—
Research Site	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02347176, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 22, 2018 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02347176 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →